Recent studies have focused on the intersection of glucagon-like peptide-1|GIP|glucagon receptor activator therapies and dopaminergic neurotransmission. While GLP activators are commonly employed for treating type 2 diabetes mellitus, their potential consequences on reward circuits, specifically mediated by DA networks, are attracting substantia… Read More